Skip to main content

Sirius Genomics Teams with UK Genomics Group

NEW YORK (GenomeWeb News) — Sirius Genomics will collaborate with a UK research group focused on human disease gene studies to develop the company’s pharmacogenomic test for patient response to a drug treatment for infection and sepsis.
 
Sirius said today that the United Kingdom Critical Care Genomics Group will help develop its test for responsiveness to recombinant actived Protein C, which is marketed by Eli Lilly under the name Xigris.
 
"The UKCCG group is conducting a large genomic association study looking at severe life-threatening infections and sepsis,” Sirius Genomics CEO Brad Popovich said in a statement. He added that the collaboration will allow the company to “significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled.”
 
Financial terms of the agreement were not disclosed.

Filed under

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.